NCT06823726

Brief Summary

The goal of this clinical trial is to learn if Taekwondo training works to help adults with ankylosing spondylitis and axial spondyloarthritis. It will also learn about the safety of Taekwondo training for these adults. The main questions are as follows:

  • Will Taekwondo training affect disease activity, functional improvement, and quality of life?
  • Will there be a difference between adults who participate in Taekwondo training and adults who continue with their usual treatment?
  • Is Taekwondo training safe for adults with ankylosing spondylitis and axial spondyloarthritis, and will it be an appropriate exercise for these adults?
  • Is there a possibility to develop a structured Taekwondo-based exercise program for adults with musculoskeletal disorders? Participants will:
  • Be a part of the Taekwondo training group or the control group for 12 weeks (where the control group will later participate in the same 12 week Taekwondo for comparison)
  • Be assessed within 2 weeks before the start of the training
  • Be assessed within 1 week after completing the training

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 2, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 12, 2025

Completed
17 days until next milestone

Study Start

First participant enrolled

March 1, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2025

Completed
Last Updated

March 25, 2025

Status Verified

March 1, 2025

Enrollment Period

5 months

First QC Date

February 2, 2025

Last Update Submit

March 20, 2025

Conditions

Keywords

TaekwondoAnkylosing SpondylitisAxial Spondyloarthritis

Outcome Measures

Primary Outcomes (3)

  • Ankylosing Spondylitis Disease Activity Score (ASDAS)

    The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index that quantifies disease activity in axial spondyloarthritis, incorporating C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) along with patient-reported outcomes. ASDAS is a continuous measure, with higher scores indicating greater disease activity. Disease activity is classified as follows: ASDAS \<1.3 (inactive disease), 1.3-2.1 (low activity), 2.1-3.5 (high activity), and \>3.5 (very high activity).

    Baseline (Pre-intervention), Week 12 (after RCT), and Week 24 (after control group Taekwondo training)

  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-reported questionnaire designed to assess disease activity in axial spondyloarthritis. It consists of six questions evaluating fatigue, spinal pain, joint pain/swelling, areas of localized tenderness, and morning stiffness (duration and severity). Scores range from 0 (no disease activity) to 10 (worst disease activity), with higher scores indicating greater disease activity.

    Baseline (Pre-intervention), Week 12 (after RCT), and Week 24 (after control group Taekwondo training)

  • Functional Assessment: Bath Ankylosing Spondylitis Functional Index (BASFI)

    The Bath Ankylosing Spondylitis Functional Index (BASFI) is a self-reported 10-item questionnaire designed to assess functional impairment in patients with axial spondyloarthritis. The questions evaluate activities related to daily living and physical function, including mobility, bending, and the ability to perform tasks. Each item is scored on a 0 to 10 scale, where 0 represents no functional limitation and 10 represents the worst functional limitation. Higher BASFI scores indicate greater functional impairment and worse physical function.

    Baseline (Pre-intervention), Week 12 (after RCT), and Week 24 (after control group Taekwondo training)

Secondary Outcomes (10)

  • Short Form-12 Health Survey Version 2 (SF-12v2)

    Baseline (Pre-intervention), Week 12 (after RCT), and Week 24 (after control group Taekwondo training)

  • Fatigue Severity Scale (FSS)

    Baseline (Pre-intervention), Week 12 (after RCT), and Week 24 (after control group Taekwondo training)

  • Ankylosing Spondylitis Quality of Life (ASQoL)

    Baseline (Pre-intervention), Week 12 (after RCT), and Week 24 (after control group Taekwondo training)

  • ASAS Health Index (ASAS-HI)

    Baseline (Pre-intervention), Week 12 (after RCT), and Week 24 (after control group Taekwondo training)

  • Bath Ankylosing Spondylitis Metrology Index (BASMI)

    Baseline (Pre-intervention), Week 12 (after RCT), and Week 24 (after control group Taekwondo training)

  • +5 more secondary outcomes

Other Outcomes (1)

  • Safety Assessments

    From enrollment to the end of intervention at 24 weeks

Study Arms (2)

Taekwondo training group

EXPERIMENTAL

Participants will undergo a 12-week Taekwondo training program, consisting of three 60-minute sessions per week.

Other: 12-week Taekwondo training

Control group

NO INTERVENTION

Participants will maintain their usual daily activities for 12 weeks without any structured exercise intervention.

Interventions

12-week structured Taekwondo training program under the supervision of qualified instructors following a standardized protocol. Frequency: 3 sessions per week Session Length: 60 minutes per session

Taekwondo training group

Eligibility Criteria

Age19 Years - 59 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Diagnosed with axial spondyloarthritis (axSpA) according to the ASAS classification criteria.
  • Age: Between 19 and 59 years old.
  • Stable medication or non-medication treatment:
  • Patients whose medication regimen has remained stable for at least the past 3 months.
  • Patients who have not taken medication for axSpA for at least the past 3 months.

You may not qualify if:

  • Participants will be excluded from the study if they meet any of the following conditions:
  • History of orthopedic surgery or fractures within the past 12 months.
  • History of cardiovascular diseases, including ischemic heart disease, cardiomyopathy, heart failure, or stroke.
  • Advanced ankylosis in ankylosing spondylitis, as confirmed by radiographic or CT imaging:
  • \- Complete ankylosis of at least two regions of the cervical, lumbar, or thoracic spine (i.e., continuous syndesmophyte formation or complete ossification between vertebral bodies).
  • Presence of other musculoskeletal abnormalities or conditions that may limit exercise performance.
  • Diagnosis of cancer within the past 5 years
  • Pregnancy
  • Regular exercise participation within the past 6 months (defined as exercising for at least 60 minutes per session, three or more times per week).
  • Major changes in medication for axial spondyloarthritis during the study period, including:
  • Initiation or discontinuation of biologic agents or targeted therapies.
  • Significant changes in the continued use of NSAIDs or sulfasalazine.
  • Significant changes in the continued use of systemic glucocorticoids.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wonju Severance Christian Hospital

Wŏnju, Gangwon-do, 26426, South Korea

RECRUITING

Related Publications (5)

  • Ortolan A, Webers C, Sepriano A, Falzon L, Baraliakos X, Landewe RB, Ramiro S, van der Heijde D, Nikiphorou E. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023 Jan;82(1):142-152. doi: 10.1136/ard-2022-223297. Epub 2022 Oct 19.

    PMID: 36261247BACKGROUND
  • Sveaas SH, Bilberg A, Berg IJ, Provan SA, Rollefstad S, Semb AG, Hagen KB, Johansen MW, Pedersen E, Dagfinrud H. High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients. Br J Sports Med. 2020 Mar;54(5):292-297. doi: 10.1136/bjsports-2018-099943. Epub 2019 Feb 11.

    PMID: 30745314BACKGROUND
  • Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P; CONSORT Group. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008 Feb 19;148(4):295-309. doi: 10.7326/0003-4819-148-4-200802190-00008.

    PMID: 18283207BACKGROUND
  • O'Dwyer T, O'Shea F, Wilson F. Exercise therapy for spondyloarthritis: a systematic review. Rheumatol Int. 2014 Jul;34(7):887-902. doi: 10.1007/s00296-014-2965-7. Epub 2014 Feb 19.

    PMID: 24549404BACKGROUND
  • Wang J, Li X, Yang F, Guo P, Ren C, Duan Z, Zhang Y. Efficacy and safety of mind-body exercise for patients with axial spondyloarthritis: a systematic review and meta-analysis. J Orthop Surg Res. 2024 Sep 28;19(1):586. doi: 10.1186/s13018-024-05072-5.

    PMID: 39342350BACKGROUND

MeSH Terms

Conditions

Spondylitis, AnkylosingAxial Spondyloarthritis

Condition Hierarchy (Ancestors)

SpondylarthropathiesSpondylarthritisSpondylitisSpinal DiseasesBone DiseasesMusculoskeletal DiseasesAnkylosisJoint DiseasesArthritis

Study Officials

  • Seoung Wan Nam, M.D., Ph.D.

    Wonju Severance Christian Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Seoung Wan Nam, M.D., Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study is designed as a single-blind, parallel-group, exploratory pilot randomized controlled trial to evaluate the efficacy and safety of a 12-week Taekwondo training program in patients with ankylosing spondylitis and axial spondyloarthritis.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor, Division of Rheumatology, Department of Internal Medicine

Study Record Dates

First Submitted

February 2, 2025

First Posted

February 12, 2025

Study Start

March 1, 2025

Primary Completion

August 1, 2025

Study Completion

November 1, 2025

Last Updated

March 25, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

De-identified participant-level data related to primary and secondary outcome measures.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
IPD and supporting information will be available after the publication of study results in a peer-reviewed journal. Data will be available for at least 5 years after publication.
Access Criteria
De-identified individual participant data (IPD) related to primary and secondary outcomes, as well as supporting documents (Study Protocol, Statistical Analysis Plan, and ICF), will be available to qualified researchers affiliated with academic or medical institutions. Researchers must submit a formal request, including a study proposal, and access will be granted upon approval by the principal investigator and institution under a data-sharing agreement.
More information

Locations